aaronmd.com
First Immunotherapy Regimen for Triple-Negative Breast Cancer Approved By FDA - Breast Cancer Treatment Surgeon Knoxville, TN - Dr. Aaron Margulies FACS
The U.S. Food and Drug Administration has recently granted its first approval to an immunotherapy regimen for Triple Negative Breast Cancer, which is significant because Triple Negative Breast Cancer tumors are generally high-grade, aggressive, and typically more likely to spread and recur. The regimen involves a combination of immunotherapy and chemotherapy—Tecentriq and Abraxane, respectively—and is …